Cure Parkinson’s have partnered with the MS Society to deliver an industry engagement workshop. The aim is to create discussion between academia and the biotech and pharmaceutical industry. This dialogue could identify opportunities and address challenges for collaboration in the use of clinical trial platforms in neurology globally.

This workshop has brought together key stakeholders and experts in Parkinson’s, Multiple Sclerosis, Motor Neurone Disease and Alzheimer’s, as well as the broader drug development community to explore:

  • How innovative academic-led clinical trial platforms can accelerate research for proprietary drugs
  • The needs of industry in order to engage in academic-led clinical trial platforms
  • How cross-sector collaboration can enhance evidence generation and patient access

At Cure Parkinson’s we believe in collaboration as a means to driving innovation and accelerating real-world impact. By combining research expertise, technical capacity and the patient voice, we can speed up the clinical development of future disease modifying therapies for people living with Parkinson’s and other neurological diseases. It is only by working together that we can shape a more connected, efficient, and impactful clinical development ecosystem that maximises chances of success for therapies that can truly make a difference to people living with neurological conditions.

Helen Matthews, CEO, Cure Parkinson’s

Finding ways to protect the brain before irreversible damage sets in is vital across all neurodegenerative conditions, and we’re so pleased we were able to come together to share our expertise. More than 150,000 people live with MS in the UK and 1 in 6 people live with a neurological condition – together this costs the UK and NHS billions, and has an enormous impact on the lives of patients and carers. Developing meaningful partnerships like this is essential to address this need and maximise the impact of charity research funding, being stretched more than ever before.

Dr Emma Gray, Director of Research at the MS Society

With events like this we hope to contribute to strengthening the opportunities for collaboration between academia, non-profit organisations and industry. Combining scientific expertise and resources, we can accelerate the development of new therapies and ensure that promising research for neurodegenerative diseases translates into patient impact faster.

Paloma Fernandez, Market Access and Industry Engagement Lead, Cure Parkinson’s


Related content